Comparative Pharmacology
Head-to-head clinical analysis: CORTENEMA versus HYDROCORTISONE SODIUM SUCCINATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTENEMA versus HYDROCORTISONE SODIUM SUCCINATE.
CORTENEMA vs HYDROCORTISONE SODIUM SUCCINATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to the glucocorticoid receptor, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, decrease cytokine production, and suppress inflammatory cell migration and activation in the colonic mucosa.
Hydrocortisone sodium succinate is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to produce anti-inflammatory, immunosuppressive, and anti-stress responses. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis.
One enema (100 mg hydrocortisone in 60 mL) administered rectally once daily, preferably at bedtime, for 21 days or until clinical response.
100–500 mg IV or IM every 2–6 hours, as needed; typical initial dose 100–250 mg IV bolus followed by 100–250 mg IV every 4–6 hours for acute conditions.
None Documented
None Documented
1.8-3.5 hours (plasma); due to rectal administration and low systemic absorption, clinical effects persist longer than plasma levels suggest
1.5-2 hours (plasma terminal); biological half-life 8-12 hours (due to intracellular effects), requiring q6-8h dosing in adrenal insufficiency
Primarily hepatic metabolism with renal excretion of inactive metabolites; <5% unchanged in urine; biliary/fecal elimination of metabolites accounts for ~80%
Renal (90-95% as metabolites, <5% unchanged); biliary/fecal <5%
Category C
Category D/X
Corticosteroid
Corticosteroid